High-affinity and soluble PDL-1 molecule
US11124557B2 · kind B2 · utility
0Cited by
1References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 9, 2016 |
| Grant date | Sep 21, 2021 |
| Priority date | — |
| Expiry date | Nov 27, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided in the present invention is a PDL-1 molecule. The affinity of the PDL-1 molecule to the PD-1 molecule is at least two times the affinity of the wild-type PDL-1 molecule to the PD-1 molecule. Meanwhile, the PDL-1 molecule of the present invention can effectively improve the killing efficiency of lymphocytes. In addition, the present invention also provides nucleic acids encoding the PDL-1 molecule of the present invention, and a complex of the PDL-1 molecules of the present invention. The PDL-1 molecule of the present invention may be used alone or in combination with other molecules.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.